Biogen Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +50

Biogen Zooms on Deal with TJ Biopharma

📈 Biogen stock rose 1.7% to $180.37 following the announcement of a definitive acquisition agreement with TJ Biopharma.

💰 Biogen agreed to acquire exclusive worldwide rights to felzartamab in exchange for an upfront payment of $100 million.

🔬 Felzartamab is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases.

🌏 The deal grants Biogen exclusive rights to the drug specifically within the Greater China Region, expanding its global opportunity.

💸 TJ Bio is eligible for up to $750 million in potential commercial and sales milestone payments, bringing total consideration to $850 million.

📜 Additional compensation includes mid-single-digit to low-double-digit percentage royalties on potential net sales in the Greater China Region.

📅 The upfront payment is expected to be recorded as an acquired in-process research and development expense in Q2 2026.

🤝 Biogen will assume existing milestone payment and royalty obligations previously held under its licensing agreement with MorphoSys (a Novartis subsidiary).

💬 Fraser Hall, President of Biogen’s Intercontinental Region, described the deal as expanding the pipeline-in-a-product nature of felzartamab for immune-mediated conditions.

📦 This acquisition aims to grow Biogen's development portfolio within a key market region.

Bullish Signals
  • Biogen stock climbed by 1.7% to $180.37 following the announcement of a definitive agreement with TJ Biopharma.
  • The acquisition grants Biogen exclusive worldwide rights to felzartamab, which is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases.
  • TJ Bio will receive an upfront payment of $100 million and is eligible for up to $750 million in potential commercial and sales milestone payments.
  • The total potential consideration for the deal reaches up to $850 million, indicating strong confidence in felzartamab's market potential.
  • Biogen will receive mid-single-digit to low-double-digit percentage royalties on potential net sales in the Greater China Region.
  • Fraser Hall, President of Biogen's Intercontinental Region, described the deal as important for further expanding the global opportunity for felzartamab.
  • Felzartamab is positioned as a 'pipeline-in-a-product' with broad applicability across a range of immune-mediated conditions.
Risk Factors
  • Biogen will record a $100 million upfront payment as an Acquired In-Process Research and Development expense in the second quarter of 2026, impacting financial results.
  • The deal obligates Biogen to assume milestone payment and royalty responsibilities under the prior MorphoSys (Novartis) licensing agreement for felzartamab.
Full Analysis
Biogen Inc. (NASDAQ: BIIB) saw its stock climb on Monday following the announcement that the company has entered into a definitive agreement to acquire TJ Biopharma's exclusive rights to felzartamab in the Greater China Region. This acquisition expands Biogen's global portfolio for the drug, which is currently being evaluated in Phase 3 clinical studies across multiple immune-mediated diseases. Under the terms of the deal, Biogen now holds exclusive worldwide rights to felzartamab, significantly broadening its development potential beyond the initial regional agreement with TJ Bio. The financial terms of the agreement include a $100 million upfront payment to TJ Bio, with eligibility for additional commercial and sales milestone payments of up to $750 million, bringing total potential consideration to as much as $850 million. Beyond these fixed payments, Biogen will also pay a mid-single-digit to low-double-digit percentage of royalties on potential net sales specifically in the Greater China Region. The upfront payment is scheduled to be recorded by Biogen as an Acquired In-Process Research and Development expense during the second quarter of 2026. Additionally, Biogen will assume all responsibilities regarding milestone payment and royalty obligations previously associated with a licensing agreement between MorphoSys, a wholly-owned subsidiary of Novartis, and TJ Bio. Fraser Hall, President of Biogen’s Intercontinental Region, commented on the significance of the deal, stating that it is important to Biogen as it further expands the global opportunity for felzartamab, describing it as a potential "pipeline-in-a-product" with broad applicability across various immune-mediated conditions. Hall expressed satisfaction in reaching the agreement with TJ Bio to grow their development portfolio within this key market. As a result of this announcement, BIIB shares increased by $3.02, or 1.7%, to reach a price of $180.37 on Monday.